SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

CPRX

Catalyst Pharmaceuticals, Inc.
BEARISH
Impact 8/10
Horizonimmediate Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss combined with withdrawn guidance and canceled earnings call is a major red flag. The May 7 announcement referenced in the filing is likely material and negative, traders should review that 8-K immediately. The stock is likely to sell off sharply on the EPS miss and uncertainty. Monitor for any further disclosures about the May 7 event.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$31.14
T+0 close · May 11, 2026 · via day close
Latest settled
+0.64%
T+20 · $31.34
Vs SPY
+2.37%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 12 $31.14entry
  2. T+1 · 6mo ago 0.00%α −0.54% · $31.14
  3. T+5 · 6mo ago +0.29%α +0.21% · $31.23
  4. T+20 · 5mo ago +0.64%α +2.37% · $31.34
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, missing the consensus estimate of $0.64 EPS and $148.2M revenue. The company withdrew forward guidance and canceled its earnings call following a May 7 announcement, creating significant uncertainty despite strong underlying product revenue growth from FIRDAPSE and AGAMREE.

Key Financial Metrics

EPS
$0.50
est $0.64 · -21.9%
Revenue
$149.4M
est $148.2M · +0.8% · +5.6% YoY
Rating
miss
Gross Margin
90.31%

Key Facts

  • GAAP diluted EPS of $0.50 missed consensus estimate of $0.64 by 21.9%
  • Total revenue of $149.4M was slightly above consensus of $148.2M (beat by 0.8%)
  • Non-GAAP diluted EPS of $0.79 was reported, but Street consensus tracks GAAP EPS for pharma
  • FIRDAPSE revenue grew 18.1% YoY to $98.9M; AGAMREE grew 66.6% to $36.7M
  • FYCOMPA revenue declined 61.3% YoY to $13.8M following loss of exclusivity
  • Company withdrew forward-looking guidance and canceled earnings call citing May 7 announcement
  • Cash and equivalents of $755.9M with no funded debt as of March 31, 2026
  • GAAP net income grew 12.3% YoY to $63.7M; operating income grew 15.6% to $73.2M

Financial Impact

GAAP diluted EPS of $0.50 vs $0.64 consensus (-21.9% miss); revenue $149.4M vs $148.2M consensus (+0.8% beat)

epsrevenueguidance

Risk Factors

  • Withdrawn guidance and canceled earnings call signal significant uncertainty
  • FYCOMPA revenue decline of 61.3% YoY due to loss of exclusivity may accelerate
  • May 7 announcement could involve regulatory, legal, or operational setback
  • EPS miss of 21.9% vs consensus undermines credibility of prior guidance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292348

Track record

16 reports on CPRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026